Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese Adults

Daniel Kim Views  

Novo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use in reducing cardiovascular problems and stroke risk in overweight and obese adults.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) stated that this approval is similar to the approval the US Food and Drug Administration (FDA) granted in March.

With this decision, Wegovy became the first GLP-1 medication to be prescribed for the prevention of cardiovascular diseases in obese patients.

Meanwhile, according to the British Heart Foundation, more than 7.6 million people in the UK suffer from cardiovascular disease each year.

The FDA’s approval was based on clinical trials showing that Wegovy reduced the risk of major cardiovascular events, such as heart attacks and strokes, by 20% compared to a placebo.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Why Your Eyelid Keeps Twitching—and When to Worry
  • Silent Spreaders: How Measles Can Infect Before Symptoms Appear
  • Eat More Eggplant—It’s Good for Your Blood and Your Heart
  • Want to Burn More Fat? Try a 30-Second Cold Shower, Experts Say
  • Bats, Fruit, and a Deadly Virus—Why Korea’s Health Officials Are on High Alert
  • Why You Crave Junk Food When You’re Sad—And What to Eat Instead

You May Also Like

  • 1
    Sizzling Summer: Southeast US Breaks Heat Records as Temperatures Soar

    LATEST 

  • 2
    GSK Korea’s New Boss: What Gunnar Riediger Brings to the Table!

    LATEST 

  • 3
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

  • 4
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 5
    Korean President Aims to Cut Red Tape and Boost Business with New Task Force

    LATEST 

Popular Now

  • 1
    Beat the Heat: Agoda's Top 5 Cool-Cation Spots for Summer Travelers!

    LATEST 

  • 2
    Brace Yourself: Prices on Everyday Goods Set to Rise as Tariffs Take Their Toll

    LATEST 

  • 3
    Former Intel Chief Drops Bombshell: Yoon's Fury Over Marine's Death Revealed!

    LATEST 

  • 4
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 5
    Buddhist Monk’s Prediction Comes True: Annuity Lottery Winner Shares His Story!

    LATEST 

Must-Reads

  • 1
    Sizzling Summer: Southeast US Breaks Heat Records as Temperatures Soar

    LATEST 

  • 2
    GSK Korea’s New Boss: What Gunnar Riediger Brings to the Table!

    LATEST 

  • 3
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

  • 4
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 5
    Korean President Aims to Cut Red Tape and Boost Business with New Task Force

    LATEST 

Popular Now

  • 1
    Beat the Heat: Agoda's Top 5 Cool-Cation Spots for Summer Travelers!

    LATEST 

  • 2
    Brace Yourself: Prices on Everyday Goods Set to Rise as Tariffs Take Their Toll

    LATEST 

  • 3
    Former Intel Chief Drops Bombshell: Yoon's Fury Over Marine's Death Revealed!

    LATEST 

  • 4
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 5
    Buddhist Monk’s Prediction Comes True: Annuity Lottery Winner Shares His Story!

    LATEST 

Share it on...